Infrastructure major HCC 's standalone net profit for the June quarter rose 17.49 percent to Rs 10.88 crore on the back of higher income. Total income from operations increased to Rs 982.45 crore from Rs 975.07 crore in the year-ago period. Praveen Sood, Group CFO of the company told CNBC-TV18 that the company's order book has logged a growth after a long time company and that going forward transport sector will lead the growth in the order book. According to him there is likelihood that the company may win arbitration awards worth Rs 3000 crore. He said the Mumbai metro project is likely to take 6-9 months to get fully mobilised and will start accruing turnover only by the fourth quarter of FY17 or the first quarter of FY18. The margins from the project are expected to be around 10-12 percent.
Friday, 29 July 2016
Home »
» Expect 10-12% margins from Mumbai metro project-:- Equity Research
Expect 10-12% margins from Mumbai metro project-:- Equity Research
02:16
Related Posts:
Tata Steel plans 2nd phase expansion of Kalinganagar plant-:- Equity Research Tata Steel is planning to initiate second phase expansion at Kalinganagar plant in Odisha to double its capacity to 6 mtpa, but has no proposal to set up another green-field steel plant in immediate future. "Sometime in ne… Read More
Look at ICICI Prudential at around Rs 280-285-:- Equity Research G Chokkalingam, Founder & MD at Equinomics Research & Advisory told CNBC-TV18, "We advised our clients not to apply to ICICI Prudential Life Insurance Company because we have found that it is quite stretched in ter… Read More
KCP Sugar may move to Rs 46-:- Equity Research G Chokkalingam, Founder & MD at Equinomics Research & Advisory told CNBC-TV18, "In KCP Sugar we successfully made money and it went to Rs 46 recently. Now again it has corrected back to around Rs 33-34 level.… Read More
Anti-dumping duty likely on certain Chinese steel products-:- Equity Research The commerce ministry has recommended imposition of anti-dumping duty on imports of steel wire rods from China to protect the interest of domestic players from cheap in-bound shipments. In its preliminary findings, the dir… Read More
Lupin off day's low after USFDA approval for anti-alzheimer drug-:- Equity Research Pharma major Lupin shares halved losses in afternoon trade Thursday on approval from the US health regulator for for anti-alzheimer drug. The stock reduced its losses to 2 percent from 4 percent intraday. "... has received… Read More
0 comments:
Post a Comment